The FDA continues to beef up their business intelligence with a new connection to be on top of safety concerns and be ahead of the game in having real time information to help in the warning and decision making processes. BD
Bridgewater, NJ (November 3, 2008) – Wolters Kluwer Health, a leading provider of information and business intelligence for students, 
professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry, today was awarded a multi-year contract to provide both prescription and patient-level data to the U.S. Food and Drug Administration (FDA) to provide the Agency with insight into the prevalence of prescription drug utilization within the U.S. population. This is the first time Wolters Kluwer Health has been selected as a primary source for this prestigious contract. 
"The FDA is always looking for ways to employ newer and better technology to support research toward a safer environment for patients and their decision to utilize our unique, longitudinal drug data fits right into this progression," said Mark Spiers, President and CEO of Wolters Kluwer Health's Healthcare Analytics business. "We were able to deliver the right balance of power and speed, that is, ongoing access to national drug utilization patterns with a turnaround that allows the FDA to act in the event of a public health concern.
0 comments :
Post a Comment